Iovance Biotherapeutics (NASDAQ: IOVA)
Iovance Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
Is Iovance Biotherapeutics Stock a Buy?
The biotech is making important breakthroughs, but is that enough?
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
This biotech's growth story is going to start moving faster, and soon.
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
There's plenty of upside with this stock, but it might take a while to realize.
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Investors should brace for dilution.
3 Monster Biotech Stocks to Buy Before 2025
These companies are nearly in the sweet spot of risk versus reward in biotech.
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
It could demonstrate a few capabilities that no other biotech has as of yet.
Why Iovance Biotherapeutics Shares Are Soaring Today
The biopharma company is proving its recently approved cancer therapy is marketable.
Valuation
Earnings Transcripts
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2021.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
IOVA earnings call for the period ending March 31, 2020.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript
IOVA earnings call for the period ending December 31, 2019.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2019 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.